Cardiovascular Disease Prevention Basic & Translational Research Laboratories | NYU Langone Health

Skip to Main Content
Center for the Prevention of Cardiovascular Disease Research Cardiovascular Disease Prevention Basic & Translational Research Laboratories

Cardiovascular Disease Prevention Basic & Translational Research Laboratories

NYU Langone’s Center for the Prevention of Cardiovascular Disease in the Division of Cardiology features several basic and translational research laboratories, led by members of our outstanding research faculty.

Berger Lab

The Berger Lab, led by Jeffrey S. Berger, MD, investigates the role of platelets in cardiovascular diseases and other inflammatory diseases.

Fisher Lab

The Fisher Lab, led by Edward A. Fisher, MD, PhD, studies lipid and lipoprotein metabolism as well as the progression and regression of atherosclerosis.

Garshick Lab

Atherosclerotic cardiovascular disease begins through damage to the endothelium. Patients with autoimmune and autoinflammatory conditions exhibit damage to the endothelium, develop accelerated atherosclerosis, and are at increased risk of heart attacks and strokes. In the laboratory of Michael S. Garshick, MD, researchers use specialized techniques to obtain and analyze vascular endothelial cells directly, thus allowing the exploration of mechanisms of atherosclerosis development in high cardiovascular risk patient populations.

Specifically, researchers are exploring endothelial cell damage in psoriasis, a skin condition shown to increase the risk of cardiovascular disease up to 3-fold higher than patients without psoriasis. Scientists are also conducting clinical trials evaluating the efficacy of medications, including aspirin and cholesterol-lowering medications (statins), to improve the endothelium in the psoriasis patient population. The goal is to develop new treatment paradigms in high-risk inflammatory populations such as psoriasis patients.

Heffron Lab

Under the direction of Sean P. Heffron, MD, the lab studies the anti-inflammatory and pro-resolving capacity of platelets in cardiovascular disease. Lab researchers have been particularly focused on how platelets mediate macrophage function to potential aid in the regression of atherosclerosis

Newman Lab

The research program of Jonathan Newman, MD, MPH, investigates cardiometabolic and environmental risk factors for cardiovascular disease, and the use of molecular technologies for simultaneous identification of underlying biological pathways, markers for noninvasive detection of cardiovascular disease, and novel targets to slow the progression of cardiovascular disease in high-risk patients with diabetes.